TRAVASE
LOE ApproachingNDATOPICALOINTMENTPriority Review
Approved
Jun 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVASE is a topical ointment small-molecule product approved by Abbott in 1969 for debridement of necrotic tissue and slough in wounds and burns. The mechanism of action involves enzymatic debriding activity to promote wound healing. This is a legacy therapeutic indicated for specialized wound care applications.
LOE Approaching
Limited commercial growth expected; team size likely lean given legacy status and approaching loss of exclusivity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRAVASE offers limited career growth due to its legacy status and approaching loss of exclusivity. Roles focus on maintaining market share in specialty wound care rather than innovation or expansion.
Product ManagerField Sales Representative
Worked on TRAVASE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.